2003A0026 - Structural and Conformational Aspects in Peptide Vaccines (HTLV-1) - Pravin TP Kaumaya

Pain Code = 3D

Approval was given by ILACUC to use 36 Squirrel monkeys for experiments "aimed at the development of synthetic peptide vaccines. The identification and characterizations of regions of viral proteins that elicit protective immune responses are at the basis of this study."

Over the last seven years, this lab has "performed extensive (indirect) studies in mice and rabbits to determine the immune responses to the HTLV-1 peptide vaccine."

The animals will be vaccinated to begin the study. At week 9, animals will be challenged intravenously with HTLV-1. The animals will be killed at week 34.

After infected with HTLV-1, "animals that exhibit signs of peripheral lymph node enlargement and /or splenomegaly will be evaluated by the veterinarian. In case of clinical disease involving but not limited to: anorexia of more than 48 hours, dehydration of more than 12-24 hours, diarrhea, neurological signs (weakness, tremors, etc.) the animals will be treated as deemed by the attending veterinarian in consultation with the PI. Animals not responding to medical treatment will be humanely killed."

P.O.E.T.s' initial request for information concerning this experiment was in August 2004. We finally received the data November 18, 2005.

Sixteen Squirrel monkeys were received from the Buckshire Corporation on October 22, 2003. All the primates received the first vaccinations on 12/22/03 and lived until a "terminal blood draw" was taken on 10/26/05, at which time all 16 primates were killed.

At this time (8/1/06) we have found no published paper concerning the results of these experiments.

UPDATE: 2006A0084, the new protocol for these experiments, is approved to use 318 rabbits and use 40 mice to bred 900 transgenic mouse. There is no mention of using primates in this protocol.

Updated: 8/7/06 - back to osu research